Inherited disorders of HDL metabolism and atherosclerosis

G Kees Hovingh1, Eric de Groot, Wim van der Steeg

  • 1Department of Vascular Medicine, Academic Medical Center, AZ Amsterdam, The Netherlands.

Insights

Genetic disorders affecting high-density lipoprotein (HDL) metabolism reveal varying atherosclerosis risks. Mutations in apoA-I, ABCA1, and LCAT accelerate atherosclerosis, while cholesteryl ester transfer protein mutations do not, informing targeted therapies.

Area of Science:

  • Cardiovascular Genetics
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Genetic disorders of HDL metabolism are rare, complicating atherosclerosis risk assessment.
  • Epidemiological studies link low HDL cholesterol to increased coronary artery disease risk.
  • Carotid artery ultrasound imaging aids risk assessment in hereditary hypo- and hyperalphalipoproteinemia.

Purpose of the Study:

  • To comprehensively summarize the assessment of atherosclerosis risk in individuals with genetic HDL metabolism disorders.
  • To compare atherosclerosis progression in carriers of mutations in apolipoprotein A-I (apoA-I), ATP binding cassette AI (ABCA1), lecithin: cholesterol acyltransferase (LCAT), and cholesteryl ester transfer protein (CETP).

Main Methods:

  • Direct comparison of carotid intima-media thickness (CIMT) data from individuals with specific genetic mutations.
  • Analysis of atherosclerosis progression in carriers versus family controls.

Main Results:

  • Mutations in apoA-I, ABCA1, and LCAT are associated with significantly accelerated atherosclerosis progression.
  • Carriers of apoA-I mutations showed the most pronounced atherosclerosis acceleration.
  • Heterozygosity for CETP mutations did not result in increased intima-media thickness progression compared to controls.
  • Hyperalphalipoproteinemia due to CETP loss-of-function showed unaltered atherosclerosis progression.

Conclusions:

  • Hypoalphalipoproteinemia linked to apoA-I, ABCA1, and LCAT mutations increases atherosclerosis progression.
  • Hyperalphalipoproteinemia due to CETP dysfunction is not associated with accelerated atherosclerosis.
  • Findings aid in prioritizing antiatherogenic therapies aimed at increasing HDL cholesterol.
Abstract

Related Concept Videos

Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...